Though several trials are investigating the combination of CDK4/6 inhibition and anti-PD-1/PD-L1 therapy in advanced breast cancer (NCT02778685, NCT04360941), such an approach has to our knowledge not been attempted in NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.